Growth Hormone-Resistant Syndromes: Long-Term Follow-Up

2009 ◽  
pp. 135-142 ◽  
Author(s):  
Steven D. Chernausek
Keyword(s):  
Growth Hormone ◽  
Long Term Follow Up

scholarly journals Long-Term Follow-Up of Growth Hormone-Producing Pituitary Carcinoma With Multiple Spinal Metastases Following Multiple Surgeries: Case Report

2013 ◽  
Vol 53 (10) ◽  
pp. 707-711 ◽  
Author(s):  
Toshihide TANAKA ◽  
Naoki KATO ◽  
Ken AOKI ◽  
Mitsuyoshi WATANABE ◽  
Takao ARAI ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Spinal Metastases ◽  
Pituitary Carcinoma ◽  
Long Term Follow Up

Ectopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results

2009 ◽  
Vol 20 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Neşe Colak Ozbey ◽  
Yersu Kapran ◽  
Alp Bozbora ◽  
Yeşim Erbil ◽  
Cemil Tascioglu ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Neuroendocrine Tumor ◽  
Hormone Secretion ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Long Term Follow Up

scholarly journals Late presentation of acromegaly in medically controlled prolactinoma patients

2016 ◽  
Vol 2016 ◽  
Author(s):  
Ekaterina Manuylova ◽  
Laura M Calvi ◽  
Catherine Hastings ◽  
G Edward Vates ◽  
Mahlon D Johnson ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Dopamine Agonists ◽  
Late Presentation ◽  
List Type ◽  
Biochemical Control ◽  
Current Recommendation ◽  
Long Term Follow Up ◽  
Learning Points

Summary Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion. The prevalence of acromegaly among patients with a newly diagnosed prolactinoma is unknown. Given the possibility of mixed GH and PRL co-secretion, the current recommendation is to obtain an insulin-like growth factor-1 (IGF-1) in patients with prolactinoma at the initial diagnosis. Long-term follow-up of IGF-1 is not routinely done. Here, we report two cases of well-controlled prolactinoma on dopamine agonists with the development of acromegaly 10–20 years after the initial diagnoses. In both patients, a mixed PRL/GH-cosecreting adenoma was confirmed on the pathology examination after transsphenoidal surgery (TSS). Therefore, periodic routine measurements of IGF-1 should be considered regardless of the duration and biochemical control of prolactinoma. Learning points: Acromegaly can develop in patients with well-controlled prolactinoma on dopamine agonists. The interval between prolactinoma and acromegaly diagnoses can be several decades. Periodic screening of patients with prolactinoma for growth hormone excess should be considered and can 
lead to an early diagnosis of acromegaly before the development of complications.

Long-Term Follow-Up of Hypopituitary Patients Treated with Human Growth Hormone

Medicine ◽  
1990 ◽  
Vol 69 (1) ◽  
pp. 46-55 ◽  
Author(s):  
SAMUEL M. LIBBER ◽  
LESLIE P. PLOTNICK ◽  
ANN J. JOHANSON ◽  
ROBERT M. BLIZZARD ◽  
PETER O. KWITEROVICH ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document